Aravive - ARAV Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARAV shares.
View ARAV analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month price targets for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $12.00. On average, they expect the company's stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 430.8% from the stock's current price.
View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts.

Aravive's stock was trading at $2.19 at the start of the year. Since then, ARAV shares have decreased by 33.3% and is now trading at $1.46.
View the best growth stocks for 2022 here.

Aravive saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 530,000 shares, an increase of 76.9% from the October 31st total of 299,600 shares. Based on an average daily volume of 627,000 shares, the short-interest ratio is currently 0.8 days.
View Aravive's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ARAV earnings forecast.

Aravive, Inc. (NASDAQ:ARAV) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.07. The business earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million. Aravive had a negative trailing twelve-month return on equity of 190.16% and a negative net margin of 695.57%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.39%), BlackRock Inc. (0.59%) and Two Sigma Advisers LP (0.14%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends.

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARAV stock can currently be purchased for approximately $1.46.

Aravive (NASDAQ:ARAV) has a market capitalization of $87.35 million and generates $7.44 million in revenue each year. The company earns $-39,150,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.